Top Markets
Coin of the day
Orexo AB Orexo AB

Orexo AB

ORX
Rank in Stocks #24940
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Share Price
$1.56
Market Cap
$54.85M
Change (1 day)
-0.29%
Change (1 year)
-29.14%
Country
SE
Trade Orexo AB (ORX)

Category

P/S ratio for Orexo AB (ORX)
P/S ratio as of 2026 TTM: 0
According to Orexo AB latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Orexo AB from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors